株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品業界動向(2010年):治療薬市場環境、主なパイプライン動向、大手製薬会社と主な合併・買収

Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions

発行 GBI Research 商品コード 139759
出版日 ページ情報 英文 177 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
医薬品業界動向(2010年):治療薬市場環境、主なパイプライン動向、大手製薬会社と主な合併・買収 Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
出版日: 2010年12月01日 ページ情報: 英文 177 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、2009年の医薬品業界動向とともに、主要薬剤の売上動向、特許失効動向を分析し、疾患別治療薬、パイプラインにおける有望薬剤、大手製薬会社の合併、買収動向、地域別法規制動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 世界の医薬品市場概要:2009年

  • イントロダクション
  • 2009年の医薬品売上トップ
  • 治療別市場シェア:2009年
  • 2009年によく売れた薬剤
  • 2009年の薬剤特許失効

第4章 主な治療環境

  • 心血管疾患治療薬
  • 呼吸器疾患治療薬
  • 筋骨格疾患治療薬
  • 癌治療薬
  • 中枢神経系疾患治療薬
  • 自己免疫疾患治療薬
  • 胃腸疾患治療薬
  • 皮膚治療薬
  • 眼科治療薬
  • 男性用治療薬
  • 婦人科治療薬
  • 血液疾患治療薬
  • 泌尿器疾患治療薬

第5章 パイプラインにおける有望薬剤

第6章 合併・買収契約動向:2009〜2010年

第7章 大手製薬会社

  • Pfizer
  • Johnson & Johnson
  • Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi-Aventis
  • AstraZeneca
  • Abbott
  • Merck
  • Bayer HealthCare

第8章 2009年の医薬品業界における主な法規制

  • 米国
  • 欧州
  • 日本

第9章 付録

図表

目次
Product Code: GBIHC045MR

Abstract

The Cardiovascular, Oncology And Central Nervous System (CNS) Therapeutics Account For More Than 50% Of The Total Sales

Cardiovascular, oncology and CNS therapeutics accounted for more than 50% of the total pharmaceutical market by indication. The three therapeutic segments accounted for 52% of the total pharmaceutical market. Cardiovascular disorder therapeutics accounted for 19% of the total market share, closely followed by oncology therapeutics with 18% and CNS therapeutics with 15% of the total pharmaceutical market share. These three major indications contribute the most to the total pharmaceutical market.

Market Share by Therapeutic Area, Global, Sales Value(%), 2009

Source: GBI Research

The high market share of cardiovascular, oncology and CNS therapeutics indicates that these therapeutic areas will decide the way forward for the global pharmaceutical industry. Majority of the pharmaceutical companies deal in these three therapeutic areas and their endeavour has been to increase and consolidate their portfolio in these therapeutic areas.

Strategic Consolidations By Major Pharmaceutical Companies Are Changing The Global Pharmaceutical Market

Strategic consolidations by major pharmaceutical companies are changing the global pharmaceutical market scenario. The major mergers and acquisitions (M&A) deals of 2009 were acquisition of Wyeth by Pfizer, Genentech by Roche and the merger of Merck and Schering-Plough. The dynamic nature of the pharmaceutical industry is expected to continue because patent expirations of major blockbuster drugs will lead the pharmaceutical companies to consider strategic consolidations to maintain their market position and, to have pipeline drugs. Pharmaceutical companies need to find alternative options to maintain their revenue generation and this can be done by acquiring regional and niche players. It is important for pharmaceutical companies to plan for the long term, so that the slow pace of research and development (R&D) can be objectively managed. The acquisition of small and niche pharmaceutical companies by major pharmaceutical companies show a very dynamic future scenario in the pharmaceutical arena.

More than 70% of the total value of M&A deals was from oncology, cardiovascular and CNS therapeutics. This indicates the high value of M&A deals in oncology, cardiovascular and CNS therapeutics.

Global M&A Deals by Therapeutic Area, 2009-2010

Source: GBI Research

The contribution in M&A deals involving oncology to the total value of M&A deals was 35%. This signifies that the oncology therapeutics area witnessed M&A deals of the highest value. This was followed by cardiovascular and CNS therapeutics contributing 20% and 19% respectively to the total value of M&A deals.

Increase In Aging Population Of Developed Countries Is Driving The Pharmaceutical Industry Towards Growth

The effect of economic recession was evident on the global pharmaceutical industry by its single digit growth in 2009. However, the steady increase in the aging population of developed countries has been driving the global pharmaceutical industry towards growth. Majority of the diseases are age-related and there has been constant increase in their prevalence due to an increase in the aging population. Greater the elderly population, greater will be the diseased population. According to the US census, the population demographics have been dramatically changing with the average age in the US, going up from 45 to 52 years between 1990 and 2005. The general population in the US has grown at 0.88% per year, however, the 65 years and above population has grown at 2.5% per year. The elderly population in the US has grown from 33 to 85 million within the time period 1990 - 2005. This growth rate is driven by 2 major factors: firstly, the baby boomer population is now entering the mid-60’s age group and secondly, the life expectancy of the general population including the elderly age group has increased from 78 to 85 years. As the lifespan of senior citizens increases, more age-related disease and illness is observed in these individuals. A combination of larger pre-disposed elderly population, along with a longer life span will drive the growth in the pharmaceutical industry. The industry will face increased demands driven by the growth in diseased population.

Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs,Top Pharma Companies and Key Mergers and Acquisitions” that provides key data, information and analysis of the major trends and issues affecting the Pharmaceutical market. The report provides a comprehensive insight into the history of Pharmaceutical Industry Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions, its uses, efficiency as well as their limitations. The report also provides a detailed analysis of Pharmaceutical Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions in terms of its market size, and the major market drivers and barriers — The report also looks into Pharmaceutical drug pipeline along with analysis on the pipeline by indication, phase of development and geography of development.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of the report includes:
- Detailed overview of pharmaceutical industry 2009-2010.
- Annualized market data
- Key market drivers and restraints, challenges and trends shaping the Pharmaceutical market
- Pipeline analysis of the along with segmentation by indication, phase and geography
- Competitive landscape analysis with competitive profiling of leading companies such as
- Analysis of M&A deals from 2009-2010 along with segmentation by value geography and companies

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Develop better strategies pharmaceutical industry
- Develop market-entry and market expansion strategies
- Understand the factors shaping the Pharmaceutical industry market
- Reinforce R&D pipeline
- Identify the key players best positioned to take the advantage of the opportunities in the pharmaceutical market
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 12
2.1 GBI Research Report Guidance 12
3 Global Pharmaceutical Market Overview 2009 13
3.1 Introduction 13
3.2 Total Sales Of Pharmaceutical Drugs In 2009 13
3.3 Market Share By Therapeutic Areas, 2009 14
3.4 Top Selling Drugs Of 2009 15
3.4.1 Lipitor (atorvastin) 15
3.4.2 Plavix (clopidrogel) 15
3.4.3 Nexium (esmoprazole) 15
3.4.4 Advair (fluticasone salmetrol) 15
3.4.5 Seroquel (quetiapine) 15
3.4.6 Diovan (valsartan) 15
3.4.7 Enbrel (etanercept) 15
3.4.8 Remicade (infliximab) 15
3.4.9 Crestor (rosuvastatin) 15
3.4.10 Zyprexa (olanzapine) 15
3.5 Key Patent Expirations Of Drugs In 2009 16
4 Key Therapeutic Landscape 17
4.1 Cardiovascular Disease Therapeutics 17
4.1.1 Drivers for Cardiovascular Therapeutics Market 18
4.1.2 Restraints For Cardiovascular Therapeutics Market 20
4.1.3 Merger And Acquisition Deals Landscape For Cardiovascular Therapeutics, 2009-2010 21
4.2 Respiratory Disease Therapeutics 23
4.2.1 Drivers For Respiratory Therapeutics Market 24
4.2.2 Restraints For Respiratory Therapeutics Market 25
4.2.3 Merger And Acquisition Deals Landscape For Respiratory Therapeutics, 2009-2010 26
4.3 Musculoskeletal Disorder Therapeutics 27
4.3.1 Drivers For Musculoskeletal Therapeutics Market 29
4.3.2 Restraints For Musculoskeletal Therapeutics Market 30
4.3.3 Merger And Acquisition Deals Landscape For Musculoskeletal Therapeutics, 2009-2010 30
4.4 Oncology Therapeutics 32
4.4.1 Drivers For Oncology Therapeutics Market 34
4.4.2 Restraints For Oncology Therapeutics Market 35
4.4.3 Merger And Acquisition Deals Landscape For Oncology, 2009-2010 36
4.5 Central Nervous System Therapeutics 38
4.5.1 Drivers For CNS Therapeutics Market 40
4.5.2 Restraints For CNS Therapeutics Market 41
4.5.3 Merger And Acquisition Deals Landscape For Central Nervous System (CNS) Therapeutics, 2009-2010 42
4.6 Autoimmune Disease Therapeutics 43
4.6.1 Drivers For Autoimmune Therapeutics Market 45
4.6.2 Restraints for Autoimmune Therapeutics Market 46
4.6.3 Merger and Acquisition Deals Landscape for Autoimmune Diseases Therapeutics, 2009-2010 47
4.7 Gastrointestinal Disorder Therapeutics 48
4.7.1 Drivers For Gastrointestinal Therapeutics Market 50
4.7.2 Restraints For Gastrointestinal Therapeutics Market 51
4.7.3 Merger And Acquisition Deals Landscape For Gastrointestinal Therapeutics, 2009-2010 51
4.8 Dermatology Therapeutics 53
4.8.1 Drivers For Dermatology Therapeutics Market 55
4.8.2 Restraints For Dermatology Therapeutics Market 56
4.8.3 Merger And Acquisition Deals Landscape For Dermatology Therapeutics, 2009-2010 56
4.9 Opthalmology Therapeutics 57
4.9.1 Drivers For Ophthalmology Therapeutics Market 60
4.9.2 Restraints For Ophthalmology Therapeutics Market 60
4.9.3 Merger And Acquisition Deals Landscape For Ophthalmology Therapeutics, 2009-2010 61
4.10 Men’s Health Therapeutics 62
4.10.1 Drivers for Men’s Health Market 64
4.10.2 Restraints for Men’s Health Market 65
4.10.3 Merger And Acquisition Deals Landscape For Men’s Health Therapeutics, 2009-2010 65
4.11 Women’s Health Therapeutics 66
4.11.1 Drivers For Women’s Health Market 68
4.11.2 Restraints For Women’s Health Market 69
4.11.3 Merger And Acquisition Deals Landscape For Women’s Health Therapeutics, 2009-2010 69
4.12 Blood Disorders Therapeutics 70
4.12.1 Drivers For Blood Disorders Therapeutics 72
4.12.2 Restraints For Blood Disorders Therapeutics 73
4.12.3 Merger And Acquisition Deals Landscape For Blood Disorders Therapeutics Market, 2009-2010 74
4.13 Urological Therapeutics Market 76
4.13.1 Drivers For Urology Therapeutics 78
4.13.2 Restraints for Urology Therapeutics Market 79
4.13.3 Merger And Acquisition Deals Landscape For Urology Therapeutics, 2009-2010 80
5 Key Promising Drugs In The Pipeline 82
5.1 Cardiovascular Therapeutics 82
5.1.1 Tekturna/Rasilez (acute heart failure) 82
5.1.2 Lixivaptan (acute heart failure) 83
5.1.3 Relaxin (acute heart failure) 83
5.1.4 Cinaciguat (acute heart failure) 84
5.1.5 Xarelto (atrial fibrillation) 85
5.1.6 Pradaxa (atrial fibrillation) 86
5.1.7 Stedicor (atrial fibrillation) 86
5.1.8 Kynapid (atrial fibrillation) 87
5.1.9 Edoxaban (atrial fibrillation) 88
5.2 Respiratory Therapeutics 89
5.2.1 Flutiform (fluticasone propionate/formoterol fumarate inhalation aerosol) (asthma) 89
5.2.2 MFF 258 (Mometasone furoate/formoterol fumarate) (asthma) 90
5.2.3 Aclidinium bromide (Chronic Obstructive Pulmonary Disease-COPD) 91
5.2.4 GW642444 (‘444) (COPD) 92
5.2.5 Iloprost (Pulmonary Arterial Hypertension) 93
5.2.6 ACT-064992 (Pulmonary Arterial Hypertension) 93
5.2.7 Denufosol Tetrasodium Inhalation Solution (INS37217) (Cystic Fibrosis) 94
5.2.8 VX-770 (Cystic Fibrosis) 95
5.3 Musculoskeletal Disorder Therapeutics 96
5.3.1 Catena/Sovrima (Idebenone) 96
5.3.2 IPlex(TM) (mecasermin rinfabate) 96
5.3.3 CG5503 97
5.3.4 Vicodin CR 97
5.3.5 T-614 (iguratimod) 98
5.4 Oncology Therapeutics 99
5.4.1 Provenge (sipuleucel-T) 99
5.4.2 Gemzar (gemcitabine hydrochloride) 100
5.4.3 Aflibercept 101
5.4.4 Recentin (Cediranib) 101
5.5 Central Nervous System (CNS) Therapeutics 102
5.5.1 Staccato Loxapine, AZ-004 (Loxapine) 102
5.5.2 Lurasidone 103
5.5.3 Clonicel 103
5.5.4 ABT-089 (Pozanicline) 104
5.5.5 Safinamide 105
5.5.6 Pimavanserin 106
5.5.7 Stedesa (Eslicarbazepine Acetate) 106
5.5.8 Comfyde (Carisbamate) 107
5.6 Autoimmune Disease Therapeutics 109
5.6.1 Benlysta (belimumab) 109
5.6.2 Voclosporin (LX211, LUVENIQ, ISA-247) 110
5.6.3 T-614 (iguratimod) 111
5.6.4 Prograf (Tacrolimus) 112
5.6.5 Mylinax (Cladribine Oral Formulation) 113
5.7 Gastrointestinal Disorder Therapeutics 114
5.7.1 Myoconda (For Crohn’s Disease) 114
5.7.2 Traficet-EN (CCX282) (For Crohn’s Disease) 115
5.7.3 Linaclotide (Linaclotide Acetate) (For Irritable Bowel Syndrome) 116
5.7.4 Asimadoline (For Irritable Bowel Syndrome) 117
5.7.5 XP19986 (For GERD) 118
5.7.6 AZD3355 (For GERD) 119
5.7.7 Prograf (Tacrolimus) (For Ulcerative Colitis) 120
5.7.8 Vedolizumab (For Ulcerative Colitis) 121
5.8 Dermatology Therapeutics 121
5.8.1 Voclosporin (LX211, LUVENIQ, ISA-247) 121
5.8.2 ABT-874 (J-695, Briakinumab) 121
5.8.3 CF-101 122
5.8.4 Orencia (abatacept, CTLA4-Ig, BMS-188667) 122
5.8.5 Cimzia (CDP870 certolizumab pegol) 122
5.8.6 Apremilast (CC10004, ACR20) 122
5.8.7 INCB18424 122
5.8.8 PH-10 122
5.8.9 Hivenyl 122
5.8.10 TF002 123
5.9 Opthalmology Therapeutics 123
5.9.1 Saflutan (tafluprost) (For Glaucoma) 123
5.9.2 Retaane (Macular Degeneration) 124
5.9.3 Photrex (SnET2) (Macular Degeneration) 124
5.9.4 Vekacia (cyclosporine A) (Allergic Conjunctivitis) 125
5.9.5 FOV1101 (Prednisporin) (Allergic Conjunctivitis) 126
5.10 Men’s Health Therapeutics 127
5.10.1 Avanafil (For Erectile Dysfunction) 127
5.10.2 Zoraxel (For Erectile Dysfunction) 128
5.11 Women’s Health Therapeutics 129
5.11.1 Visanne (For Endometriosis) 129
5.11.2 Proellex (For Endometriosis) 129
5.11.3 Viviant (bazedoxifene) (For Osteoporosis) 130
5.12 Blood Disorders Therapeutics 131
5.12.1 Hematide (peginesatide) (For Anemia) 131
5.12.2 NecLip-rFVIIa (LongSeven) (For Hemophilia) 132
5.13 Urological Disorders Therapeutics 132
5.13.1 NX-1207 (For BPH) 132
5.13.2 YM178 (For Urinary Incontinence) 133
5.13.3 CXA-101(For UTI) 134
6 Merger and Acquisition Deals Landscape, 2009-2010 135
6.1 Key Mergers And Acquisitions Deals Of 2009 137
6.1.1 Pfizer Completes Acquisition Of Wyeth 137
6.1.2 Roche Acquires Genentech 138
6.1.3 Merck Completed Merger With Schering Plough Corporation 138
6.1.4 Abbott Acquires Solvay Pharmaceuticals 139
6.1.5 GSK Acquired Stiefel Laboratories 139
7 Major Pharmaceutical Companies 140
7.1 Pfizer 140
7.1.1 Annual Revenue 140
7.1.2 Top Selling Drugs of Pfizer 140
7.1.3 Key Pipeline Drugs Of Pfizer 141
7.1.4 Merger And Acquisition Deals Landscape Of Pfizer 142
7.2 Johnson and Johnson (J&J) 143
7.2.1 Annual Revenue 143
7.2.2 Top Selling Drugs of J&J 143
7.2.3 Key Pipeline Drugs Of J&J 144
7.2.4 Merger And Acquisition Deals Landscape Of J&J 145
7.3 Roche 146
7.3.1 Annual Revenue 146
7.3.2 Top Selling Drugs Of Roche 146
7.3.3 Key Pipeline Drugs Of Roche 147
7.3.4 Merger And Acquisition Deals Landscpae Of Roche 148
7.4 GlaxoSmithKline (GSK) 148
7.4.1 Annual Revenue 148
7.4.2 Top Selling Drugs Of GSK 148
7.4.3 Key Pipeline Drugs Of GSK 150
7.4.4 Merger And Acquisition Landscape Of GSK 150
7.5 Novartis 151
7.5.1 Annual Revenue 151
7.5.2 Top Selling Drugs Of Novartis 151
7.5.3 Key Pipeline Drugs Of Novartis 152
7.5.4 Merger And Acquisition Deals Landscape Of Novartis 153
7.6 Sanofi-Aventis 153
7.6.1 Annual revenues 153
7.6.2 Top Selling Drugs Of Sanofi-Aventis 153
7.6.3 Key Pipeline Drugs Of Sanofi-Aventis 155
7.6.4 Merger and Acquisition Deals Landscape of Sanofi-Aventis 155
7.7 AstraZeneca 156
7.7.1 Annual Revenue 156
7.7.2 Top Selling Drugs 156
7.7.3 Key Pipeline Drugs Of Astrazeneca 158
7.7.4 Merger And Acquisition Deals Landscape Of Astrazeneca 158
7.8 Abbott 158
7.8.1 Annual Revenues 158
7.8.2 Top Selling Drugs Of Abbott 158
7.8.3 Key Pipeline Drugs Of Abbott 159
7.8.4 Merger And Acquisition Deals Landscape Of Abbott 159
7.9 Merck 160
7.9.1 Annual Revenue 160
7.9.2 Top Selling Drugs Of Merck 160
7.9.3 Key Pipeline Drugs Of Merck 161
7.9.4 Merger and Acquisition Deals Landscape of Merck 161
7.10 Bayer HealthCare 162
7.10.1 Annual Revenue 162
7.10.2 Top Selling Drugs Of Bayer HealthCare 162
7.10.3 Key Pipeline Products Of Bayer Healthcare 163
7.10.4 Merger And Acquisition Deals Landscape Of Bayer 163
8 Key Regulations In Pharmaceutical Industry In 2009 164
8.1 Key Regulations in Us In 2009 164
8.1.1 Biologic License Applications (BLAs) Approved By FDA In 2009 164
8.1.2 New Molecular Entities (NMEs) Approved By FDA In 2009 165
8.1.3 Key Drug Recalls In US 166
8.1.4 Key Black Box Warnings issued by FDA in 2009 167
8.2 Key Regulations In Europe In 2009 169
8.2.1 Key Drug Approvals By European Medicines Agency (EMA) In 2009 169
8.2.2 Key Drug Recall In EU 170
8.3 Key Regulations In Japan In 2009 170
8.3.1 Key New Drug Application (NDA) And Drug Approvals By Ministry Of Health, Labour And Welfare (MHLW) Of Japan in 2009 170
9 Pharmaceutical Industry Yearbook 2010: Appendix 172
9.1 Market Definitions 172
9.2 Abbreviations 172
9.3 Research Methodology 173
9.3.1 Coverage 173
9.3.2 Secondary Research 173
9.3.3 Primary Research 173
9.3.4 Forecasts 174
9.4 Contact Us 177
9.5 Disclaimer 177
9.6 Sources 177

1.1 List of Tables
Table 1: Pharmaceutical Market, Major Drug Patent Expirations,Global, 2009 16
Table 2: Top Selling Drugs of Pfizer, Sales Value ($m), 2009 140
Table 3: Key Pipeline Drugs Of Pfizer, 2009 141
Table 4: Top Selling Drugs of JNJ,Sales Value ($m), 2009 143
Table 5: Key Pipeline Drugs of Johnson and Johnson, 2009 144
Table 6: Top Selling Drugs of Roche, Sales Value ($m), 2009 146
Table 7: Key Pipeline Drugs of Roche, 2009 147
Table 8: Top Selling Drugs of GSK, Sales Value ($m), 2009 148
Table 9: Key Pipeline Drugs of GSK, 2009 150
Table 10: Top Selling Drugs of Novartis, Sales Value ($m), 2009 151
Table 11: Key Pipeline Drugs Of Novartis, 2009 152
Table 12: Top Selling Drugs of Sanofi-Aventis,Sales Value ($m), 2009 153
Table 13: Key Pipeline drugs of Sanofi-Aventis, 2009 155
Table 14: Top Selling Drugs of AstraZeneca, Sales Value ($m), 2009 156
Table 15: Key Pipeline Drugs of AstraZeneca, 2009 158
Table 16: Top Selling Drugs of Merck ,Sales Value ($m), 2009 160
Table 17: Key Pipeline Drugs of Merck, 2009 161
Table 18: Top Selling Drugs of Bayer HealthCare, Sales Value ($m), 2009 162
Table 19: Key Pipeline Drugs of Bayer, 2009 163
Table 20: BLAs Approved by FDA in 2009 164
Table 21: NME Approved by FDA in 2009 165
Table 22: Key Warning Letters by FDA to Pharmaceutical Companies, 2009 168
Table 23: Key Drug Approvals by EMA in 2009 169
Table 24: Key NDA and Drug Approvals by MHLW, Japan, 2009 171

1.2 List of Figures
Figure 1: Global Pharmaceutical Market, Market Share of Top Manufacturers(%), 2009 13
Figure 2: Global Pharmaceutical Industry, Market Share by Therapeutic Area, Global, Sales Value(%), 2009 14
Figure 3: Cardiovascular Therapeutics Market, Global, Market Share of Top Manufacturers, 2009 17
Figure 4: Cardiovascular Therapeutics ,Global, Market Share by Indication(%), 2009 and 2016 18
Figure 5: Cardiovascular Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 18
Figure 6: Cardiovascular Therapeutics Market,Global, M&A Deals by Geography, 2009 -2010 21
Figure 7: Cardiovascular Therapeutics Market,Global, M&A Deals by Value ($), 2009-2010 22
Figure 8: Respiratory Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 23
Figure 9: Respiratory Therapeutics ,Global, Market Share by Indication(%), 2009 and 2016 24
Figure 10: Respiratory Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 24
Figure 11: Respiratory Therapeutics Market, Global, M&A Deals by Geography, 2009-2010 26
Figure 12: Respiratory Therapeutics Market, Global, M&A Deals by Value($), 2009-2010 26
Figure 13: Musculoskeletal Disorder Therapeutics Market, Global, Market Share of Top Manufacturers, 2009 28
Figure 14: Musculoskeletal Therapeutics , Market Share by Indication,Global, 2009 and 2016 29
Figure 15: Musculoskeletal Disorder Therapeutics Market, Global, Drivers and Restraints, 2009-2010 29
Figure 16: Musculoskeletal Therapeutics Market, Global, M&A Deals by Geography (2009-2010) 31
Figure 17: Musculoskeletal Therapeutics Market, Global, M&A Deals by Value ($), 2009-2010 32
Figure 18: Oncology Therapeutics Market, Global, Market Share of Top Manufacturers(%), 2009 33
Figure 19: Global Oncology Market, Global, Market Share by Indication (%), 2009 and 2016 33
Figure 20: Oncology Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 34
Figure 21: Oncology Therapeutics Market, Global, M&A Deals by Geography, 2009-2010 36
Figure 22: Oncology Therapeutics Market, Global, M&A Deals by Value ($), 2009-2010 37
Figure 23: CNS Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 38
Figure 24: CNS Therapeutics Market, Global, Market Share by Indication (%), 2009 and 2016 39
Figure 25: CNS Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 40
Figure 26: CNS Therapeutics Market, Global, M&A Deals by Geography, 2009-2010 42
Figure 27: CNS Therapeutics Market, Global, M&A Deals by Value ($), 2009 43
Figure 28: Autoimmune Disease Therapeutics Market, Global, Market Share of Top Manufacturers(%), 2009-2010 44
Figure 29: Autoimmune Disorders Market, Global, Sales by Indication (%), 2009 and 2016 45
Figure 30: Autoimmune Disease Therapeutics Market, Global, Market Drivers and Restraints, 2009 45
Figure 31: Autoimmune Disease Therapeutics Market, Global ,M&A Deals by Geography,2009 47
Figure 32: Autoimmune Disease Therapeutics Market, Global ,M&A Deals by Value($), 2009 48
Figure 33: Gastrointestinal Therapeutics Market, Market Share of Top Manufacturers (%), 2009 49
Figure 34: Gastrointestinal Therapeutics Market, Global, Sales by Indication (%), 2009 and 2016 49
Figure 35: Gastrointestinal Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 50
Figure 36:Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Geography, 2009 52
Figure 37:Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Value ($), 2009 52
Figure 38: Dermatology Therapeutics Market, Global, Market Share of Top Manufacturers, 2009 53
Figure 39: Dermatology Therapeutics Market, Global, Market Share by Indication (%), 2009 and 2016 54
Figure 40: Dermatology Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 55
Figure 41: Dermatology Therapeutics Market , Global, M&A Deals by Geography, 2009-2010 56
Figure 42: Dermatology Therapeutics Market , Global, M&A Deals by Value ($), 2009 57
Figure 43: Ophthalmology Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 58
Figure 44: Ophthalmology Therapeutics Market, Global, Sales by Indication (%), 2009 and 2016 59
Figure 45: Global Ophthalmology Therapeutics Market, Drivers and Restraints, 2009 60
Figure 46: Ophthalmology Therapeutics Market, Global, M&A deals by Geography ($), 2009 61
Figure 47: Ophthalmology Therapeutics Market, Global, M&A deals by Value ($), 2009 62
Figure 48: Men’s Health Market, Global, Market Share of Top Manufacturers(%), 2009 63
Figure 49: Men’s Health Market, Global, Sales by Indication (%), 2009 and 2016 63
Figure 50: Men’s Health Market, Global, Market Drivers and Restraints, 2009-2010 64
Figure 51: Men’s Health Market, Global, M&A Deals by Geography(%), 2009-2010 65
Figure 52: Men’s Health Market,Global, M&A Deals by Value,($), 2009-2010 66
Figure 53: Women’s Health Market, Global, Market Share of Top Manufacturers, 2009 67
Figure 54: Women’s Health Market, Global, Market Share by Indication (%), 2009 and 2016 67
Figure 55: Women’s Health Market, Global, Drivers and Restraints, 2009-2010 68
Figure 56: Women’s Health Market, Global, M&A Deals by Geography(%), 2009-2010 69
Figure 57: Women’s Health Market, Global, M&A Deals by Geography, ($), 2009-2010 70
Figure 58: Blood Disorders Market, Global, Market Share of Top Manufacturers(%), 2009 71
Figure 59: Blood Disorder Therapeutics Market, Global, Market Share by Indication (%), 2009 and 2016 71
Figure 60: Blood Disorders Market, Global, Market Drivers and Restraints, 2009-2010 72
Figure 61: Blood Disorders Market, Global, Major M&A Deals by Geography, (%), 2009-2010 74
Figure 62: Blood Disorders Market, Global, M&A Deals by Value, ($), 2009-2010 75
Figure 63: Urological Disorders Market, Global, Market Share of Top Manufacturers(%), 2009 76
Figure 64: Urological Therapeutics Market, Global, Sales by Indication (%), 2009 and 2016 77
Figure 65: Urological Disorders Market, Global, Market Drivers and Restraints, 2009-2010 78
Figure 66: Urological Disorders Market,Global, Major M&A Deals by Geography, 2009-2010 80
Figure 67: Urological Disorders Market, Global, M&A Deals by Value($),2009-2010 81
Figure 68: M&A Deals by Therapeutic Area, Global, Market Share(%), 2009-2010 135
Figure 69: Major M&A Deals by Geography, Global, 2009-2010 136
Figure 70: Major M&A Deals by Value($), Global, 2009-2010 137
Figure 71: GBI Research Market Forecasting Methodology, 2010 176

Back to Top